A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Clinical trial NCT05142696 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05142696
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-13
- Primary completion
- 2028-03-07
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.